Comparative Pharmacology
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL versus TEVETEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL versus TEVETEN.
AZILSARTAN MEDOXOMIL vs TEVETEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.
Selective angiotensin II receptor type 1 (AT1) antagonist, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
40 mg orally once daily. May increase to 80 mg once daily if needed.
400-800 mg orally once daily; can be divided twice daily if needed for adequate blood pressure control.
None Documented
None Documented
Terminal half-life approximately 11 hours; supports once-daily dosing with sustained antihypertensive effect over 24 hours.
Clinical Note
moderateAzilsartan medoxomil + Benzydamine
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benzydamine."
Clinical Note
moderateAzilsartan medoxomil + Droxicam
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Droxicam."
Clinical Note
moderateAzilsartan medoxomil + Loxoprofen
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Loxoprofen."
Clinical Note
moderateTerminal elimination half-life is approximately 7-8 hours in patients with normal renal function, supporting once-daily dosing.
Biliary/fecal (55% unchanged), renal (42% as inactive metabolites, <1% unchanged)
Renal (approximately 60% as unchanged drug) and biliary/fecal (approximately 40%).
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker
Azilsartan medoxomil + Clonixin
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Clonixin."